ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CTTC Calmare Therapeutics Inc (CE)

0.000001
0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Calmare Therapeutics Inc (CE) USOTC:CTTC OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)

01/04/2014 9:13pm

Edgar (US Regulatory)


Calculation of Registration Fee
Title of Each Class of Securities Offered Maximum
Aggregate Offering
Price
Amount of
Registration
Fee
Credit Suisse FI Enhanced Big Cap Growth Exchange Traded Notes due October 22, 2018 Linked to the Russell 1000 ® Gross Index Total Return $4,689,680 $604.03

Filed pursuant to Rule 424(b)(2)

Registration Statement No. 333-180300-03

April 1, 2014

Pricing Supplement Addendum No. 17 dated April 1, 2014

To Pricing Supplement No. ETN-11/A dated October 21, 2013,

To Prospectus Supplement dated March 23, 2012 and

To Prospectus dated March 23, 2012

 


Credit Suisse FI Enhanced Big Cap Growth Exchange Traded Notes due October 22, 2018 Linked to the Russell 1000 ® Gross Index Total Return (“ETNs”)

 

Issuer: Credit Suisse AG, acting through its Nassau Branch
   
CUSIP/ISIN: 22539T563/US22539T5636
   
NYSE Arca Ticker Symbol: FIBG
   
Aggregate Offering Price of ETNs: $4,689,680
   
Public Offering Price per ETN: $46.8968
   
Principal Amount of ETNs: $4,078,000
   
Principal Amount per ETN: $40.78
   
Trade Date: April 1, 2014
   
Settlement Date: April 1, 2014
   
Agent: Credit Suisse Securities (USA) LLC (“CCSU”), an affiliate of the Issuer
   
Proceeds to Issuer: 100.00% of the Aggregate Offering Price
   
Agent’s Discount and Commission: 0.00%.  However, CSSU is expected to charge normal commissions for the purchase of the ETNs and may receive all or a portion of the investor fee. In addition, CSSU our agent for any repurchases at the investor’s option may charge investors a fee, with respect to each ETN that is redeemed prior to the Maturity Date, equal to the product of (i) 0.05% times (ii) the Closing Level of the Index on the Early Redemption Valuation Date or Accelerated Valuation Date, as the case may be, times (iii) the Index Units as of the immediately preceding Trading Day. For a further description of the fees and commissions payable pertaining to the ETNs please see the section entitled “Supplemental Plan of Distribution (Conflicts of Interest)” in the accompanying pricing supplement.

You may lose some or all of your principal if you invest in the ETNs. See “Risk Factors” beginning on page PS-25 of the accompanying pricing supplement for risks relating to an investment in the ETNs.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this pricing supplement addendum, or the accompanying pricing supplement, prospectus supplement and prospectus, is truthful or complete. Any representation to the contrary is a criminal offense. The ETNs are not deposit liabilities and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction.

Credit Suisse

1 Year Calmare Therapeutics (CE) Chart

1 Year Calmare Therapeutics (CE) Chart

1 Month Calmare Therapeutics (CE) Chart

1 Month Calmare Therapeutics (CE) Chart

Your Recent History